US3535422A - Stable benzoyl peroxide composition - Google Patents
Stable benzoyl peroxide composition Download PDFInfo
- Publication number
- US3535422A US3535422A US711861A US3535422DA US3535422A US 3535422 A US3535422 A US 3535422A US 711861 A US711861 A US 711861A US 3535422D A US3535422D A US 3535422DA US 3535422 A US3535422 A US 3535422A
- Authority
- US
- United States
- Prior art keywords
- benzoyl peroxide
- composition
- water
- weight
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title description 79
- 239000004342 Benzoyl peroxide Substances 0.000 title description 63
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 title description 63
- 235000019400 benzoyl peroxide Nutrition 0.000 title description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 22
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 22
- 239000003974 emollient agent Substances 0.000 description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 16
- 239000000470 constituent Substances 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 16
- 206010000496 acne Diseases 0.000 description 14
- 229910052717 sulfur Inorganic materials 0.000 description 14
- 239000011593 sulfur Substances 0.000 description 14
- 208000002874 Acne Vulgaris Diseases 0.000 description 13
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 11
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 11
- 229960002216 methylparaben Drugs 0.000 description 11
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 239000008367 deionised water Substances 0.000 description 10
- 229910021641 deionized water Inorganic materials 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 229940075507 glyceryl monostearate Drugs 0.000 description 8
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 8
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 8
- 235000021355 Stearic acid Nutrition 0.000 description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 7
- 239000008117 stearic acid Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 150000002978 peroxides Chemical class 0.000 description 6
- 210000002374 sebum Anatomy 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 230000003325 follicular Effects 0.000 description 5
- 239000003410 keratolytic agent Substances 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 206010039792 Seborrhoea Diseases 0.000 description 4
- -1 aliphatic alcohols Chemical class 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WDQOEAOLRIMQDA-UHFFFAOYSA-N 3-methylbutyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCC(C)C WDQOEAOLRIMQDA-UHFFFAOYSA-N 0.000 description 2
- 206010000503 Acne cystic Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229940074046 glyceryl laurate Drugs 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 230000001530 keratinolytic effect Effects 0.000 description 2
- 230000035984 keratolysis Effects 0.000 description 2
- CZMCGSFFXVXBKG-UHFFFAOYSA-N octadecanoic acid;propane-1,3-diol Chemical compound OCCCO.CCCCCCCCCCCCCCCCCC(O)=O CZMCGSFFXVXBKG-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- MOQRZWSWPNIGMP-UHFFFAOYSA-N pentyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCC MOQRZWSWPNIGMP-UHFFFAOYSA-N 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- TZYRSLHNPKPEFV-UHFFFAOYSA-N 2-ethyl-1-butanol Chemical compound CCC(CC)CO TZYRSLHNPKPEFV-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- AMEMLELAMQEAIA-UHFFFAOYSA-N 6-(tert-butyl)thieno[3,2-d]pyrimidin-4(3H)-one Chemical compound N1C=NC(=O)C2=C1C=C(C(C)(C)C)S2 AMEMLELAMQEAIA-UHFFFAOYSA-N 0.000 description 1
- 206010000513 Acne pustular Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CMCJFUXWBBHIIL-UHFFFAOYSA-N Propylene glycol stearate Chemical compound CC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CMCJFUXWBBHIIL-UHFFFAOYSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- 229940037626 isobutyl stearate Drugs 0.000 description 1
- 229940033357 isopropyl laurate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- 229940089350 klaron Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- CPXCDEMFNPKOEF-UHFFFAOYSA-N methyl 3-methylbenzoate Chemical compound COC(=O)C1=CC=CC(C)=C1 CPXCDEMFNPKOEF-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- DPBVJRXPSXTHOL-UHFFFAOYSA-N propyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCC DPBVJRXPSXTHOL-UHFFFAOYSA-N 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/38—Percompounds, e.g. peracids
Definitions
- a therapeutic composition for the treatment of acne comprising a uniform dispersion of benzoyl peroxide in a fluid medium containing water and at least one organic emollient is disclosed.
- the composition contains from about 1 to 25% by weight benzoyl peroxide, from about 2 to 25 by weight of the organic emollients and from about 50 to 90% by weight water.
- the organic emollient constituents of the composition are saturated organic compounds that are inert, non-polar and non-ionic with respect to the other constituents of the composition and that have a boiling point higher than water, whereby the composition is stable in storage without the addition of a stabilizer thereto.
- Acne and seborrhea are conditions of the human skin characterized by an excessive flow of sebum, or skin oil, from the sebaceous glands which are located in the pilosebaceous apparatus.
- the channel through which sebum reaches the skin surface is the duct of the hair follicle.
- the presence of excessive amounts of sebum in the duct and on the skin acts to block or stagnate the continuous flow of sebum from the follicular duct, thus producing a thickening of the sebum which becomes a solid plug known as a comedone.
- hyperkeratinization of the follicular opening is stimulated, thus completely closing the duct.
- the usual result is a papule, a pustule, or a cyst, often contaminated with bacteria which cause secondary infections.
- ком ⁇ онентs are employed in the treatment of acne and seborrhea to prevent the blocking of the follicular duct, to reopen the duct once it has become blocked, to act against the infecting bacteria or the thickened sebum, or to provide combinations of each of these actions.
- the horny outer layer of the skin is formed of dead cells composed largely of a substance known as keratin, and therapeutic agents which act to prevent the blocking of the follicular duct by promoting the removal or sluffing off of excess keratin are known as keratolytic agents.
- benzoyl peroxide is substantially insoluble in water, and it is ordinarily incorporated in conventional ointments and creams containing water and other common organic and inorganic constituents by first dissolving the peroxide in a volatile organic solvent such as chloroform which is then mixed with the other aqueous and nonaqueous ingredients of the composition. The resulting mixture is then permitted to stand or age for several days in order to allow the organic solvent to evaporate from the composition before it is applied to the skin.
- a volatile organic solvent such as chloroform
- compositions containing benzoyl peroxide, Water and other common organic and mineral components of such preparations display a gradual loss of potency, and that after about four months the level of benzoyl peroxide remaining in the composition is below that necessary to produce the desired therapeutic eiiects.
- Any attempt to stabilize the composition by adding antioxidants thereto inhibits the acitivity of the benzoyl peroxide and defeats the purpose of the composition. Consequently, it is the usual practice when preparing therapeutic compositions containing benzoyl peroxide to supply the user with separate packages of benzoyl peroxide and a base formulation which are mixed together just prior to using the composition.
- compositions containing water, organic emollients and therapeutically effective benzoyl peroxide can be prepared which are stable over a period of time at least equal to the normal commercial life of ordinary pharmaceutical preparations. Moreover, these new compositions display full stability with respect to the benzoyl peroxide component thereof even when subjected to temperatures higher than those normally expected in the ordinary use of the product.
- the stability of our new benzoyl peroxide-containing composition is predicated on our discovery that if the base or fluid medium in which the benzoyl peroxide is dispersed contains only water and organic emollients which are substantially inert, non-polar and non-ionic with respect to the other constituents of the composition and which have a boiling point higher than water, the benzoyl peroxide constituent thereof will not be decomposed nor react with the base, and therefore will be able to exert its full therapeutic activity as an oxidizing and kerotolytic agent when applied topically to the skin of a patient.
- the composition of our invention comprises a dispersion of finely divided particles of benzoyl peroxide in a water-containing fluid medium that is substantially free of dissolved benzoyl peroxide, the composition containing from about 1 to 25% by weight of benzoyl peroxide, from about 2 to 25% by weight of at least one organic emollient that is substantially inert, non-polar and non-ionic with respect to the other constituents of the composition and from about 50 to 90% by weight water.
- composition of our invention must contain sufiicient benzoyl peroxide to be therapeutically effective, and should not contain more peroxide than can be uniformly dispersed in the fluid base to form a smoothly spreadable cream or ointment.
- these considerations dictate that the composition contain at least about 1% and not more than about 25% by weight benzoyl peroxide, and we presently prefer that the composition contain from about 5 to about by weight benzoyl peroxide.
- the benzoyl peroxide constituent of the composition should be of high purity (that is, in the order of 98:1% (C H CO) O and in the form of relatively finely divided crystalline particles.
- the composition also contains from about 2 to by weight of at least one, and usually several, of certain organic emollients.
- the organic emollient constituents of the composition should be selected from among those which are inert, and which are substantially non-ionic and non-polar, with respect to benzoyl peroxide and the other ingredients of the composition, and further from among those which have a boiling point higher than water.
- inert refers to organic emollients which do not react chemically with benzoyl peroxide or with the other constituents of the composition at ambient temperature and pressure. In this connection, we have found that the presence of unsaturated carbon atoms in the emollient has an adverse effect on the stability and shelf life of the composition.
- the emollients preferably should be saturated organic compounds; that is, organic compounds that have no double or triple carbon to carbon atom bonds in the hydrocarbon chain.
- the terms non-ionic and non-polar as employed herein refer to emollient organic compounds which are insoluble in water at ordinary temperatures, or if soluble in water do not ionize therein to an appreciable degree.
- the requirement that the emollients have a boiling point higher than water is of importance to insure that some of the emollient will remain on the skin of the patient as a vehicle for the benzoyl peroxide after the evaporation of the Water content of the composition therefrom.
- Emollient compounds meeting these criteria include, but are not limited to, aliphatic alcohols having from 4 to 20 carbon atoms, glycols having 2 to 3 carbon atoms, fatty acids having from 12 to 20 carbon atoms, and the esters of said acids.
- organic compounds representative of those useful in compositions of our invention include, but are not limited to, butyl alcohol, isobutyl alcohol, amyl alcohol, iso-amyl alcohol, hexyl alcohol, isohexyl alcohol, and the essentially water-insoluble higher aliphatic alcohols which are soluble in or softened by the aforementioned alcohols; ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol and the like; lauric acid, myristic acid, palmitic acid, stearic acid, and the like; and ethyl laurate, isopropyl laurate, ethyl myristate, n-propyl myristate, isopropyl myristate, ethyl palmitate, isopropyl palmitate, methyl palmitate, methyl stearate, ethyl stearate, isopropyl stearate, butyl stearate, isobutyl stea
- the composition contains from about 50 to by weight water in which benzoyl peroxide is substantially insoluble.
- it also contains emulsifiers for the aqueous and non-aqueous phases of the composition, for example, polyethylene glycol 1000 monostearate, as well as preservatives such as methyl paraben (the methyl ester of parahydroxybenzoic acid) to prevent mold growth.
- the composition also advantageously contains from about 1 to 25% by weight of finely divided sulfur, and preferably from about 2 to 10% by weight of precipitated sulfur, U.S.P. grade.
- Sulfur is an antimicrobial and keratolytic agent that has long been used in the treatment of acne. Although it is not known precisely how sulfur exerts its keratolytic effect on the skin, it is through that hydrogen sulfide, which is formed when sulfur is in contact with animal tissue, reacts with alkali in tissue fluids to produce active sulfides which, in turn, promote keratolysis. The combination of precipitated sulfur with benzoyl peroxide produces significantly greater keratolysis than either substance will when used alone. The mechanism responsible for this result is not known.
- benzoyl peroxide facilitates the reaction between the active sulfides and keratin, or benzoyl peroxide may have some direct effect or keratin which makes it more susceptible to the action of the sulfide.
- benzoyl peroxide and sulfur in our new composition gives the composition properties which are especially useful in the treatment of acne.
- the composition is prepared by carefully and thoroughtly blending the benzoyl peroxide, organic emollient, water and other constituents of the composition.
- the fluid medium in which the benzoyl peroxide is to be dispersed is first prepared by forming an emulsion of the aqueous and non-aqueous phases of the fluid medium.
- the benzoyl peroxide and sulfur, if any, constituents of the composition are then added to the emulsion and thoroughly blended therewith to form the therapeutic compostion of our invention.
- the benzoyl peroxide constituent is in the form of dry, finely divided crystalline particles no further treatment of the composition is required, however, When the benzoyl peroxide is in the form of relatively coarse crystals packaged wet With water, the mixture of benzoyl peroxide and water is thoroughly mixed with a previously emulsified mixture of the emollient and water constituents of the composition, and the composition is then milled to physically reduce the particle size of the benzoyl peroxide crystals so that substantially all of the particles are smaller than 0.25 mm. in size.
- composition is applied topically to the skin of the patient by rubbing the cream or ointment in well,
- composition of our invention contains 5% benzoyl peroxide and 2% sulfur.
- compositions containing 20% benzoyl peroxide and up to 25% sulfur have been used by individuals with dark, very oily skin and by those who have developed resistance to compositions of lesser strength, and compositions containing only 1.25% benzoyl peroxide and 0.5% sulfur have been used by individuals with fair and delicate skin.
- the compositions prepared in accordance with our invention are stable and retain full potency of the benzoyl peroxide constituent thereof for a period of time, i.e., for about eight years or more, which far exceeds the normal requirements for a pharmaceutical product.
- a therapeutic composition for the treatment of acne that is stable in storage Without the addition of a stabilizer thereto which consists of a uniform dispersion of finely divided particles of crystalline benzoyl peroxide in a fluid medium consisting essentially of water and an organic emollient selected from the group consisting of saturated aliphatic alcohols having from 4 to 20 carbon atoms, glycols having 2 to 3 carbon atoms, saturated fatty acids having from 12 to 20 carbon atoms, lower alkyl and glyceryl esters of said fatty acids having from 12 to 20 carbon atoms, and mixtures thereof, said organic emollient being inert, non-polar and non-ionic with respect to the other constituents of the composition and that have a boiling point higher than water, said composition containing from about 1 to 25% by weight benzoyl peroxide, from about 2 to 25% by weight of said organic emollient and from about 50 to 90% by weight water.
- an organic emollient selected from the group consisting of saturated alipha
- composition according to claim 1 in which the composition contains from about 5 to 10% by weight benzoyl peroxide.
- composition according to claim 1 in which the composition contains from about 1 to 25% by weight finely divided sulfur.
- composition contains from about 5 to 10% by weight benzoyl peroxide and from about 2 to 10% by weight finely divided sulfur.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
United States Patent O US. Cl. 424--164 4 Claims ABSTRACT OF THE DISCLOSURE A therapeutic composition for the treatment of acne comprising a uniform dispersion of benzoyl peroxide in a fluid medium containing water and at least one organic emollient is disclosed. The composition contains from about 1 to 25% by weight benzoyl peroxide, from about 2 to 25 by weight of the organic emollients and from about 50 to 90% by weight water. The organic emollient constituents of the composition are saturated organic compounds that are inert, non-polar and non-ionic with respect to the other constituents of the composition and that have a boiling point higher than water, whereby the composition is stable in storage without the addition of a stabilizer thereto.
BACKGROUND OF THE INVENTION This is a continuationin-part of our co-pending United States patent application Ser. No. 538,567, filed Mar. 30, 1966, now abandoned, entitled Therapeutic Composition.
Acne and seborrhea are conditions of the human skin characterized by an excessive flow of sebum, or skin oil, from the sebaceous glands which are located in the pilosebaceous apparatus. The channel through which sebum reaches the skin surface is the duct of the hair follicle. The presence of excessive amounts of sebum in the duct and on the skin acts to block or stagnate the continuous flow of sebum from the follicular duct, thus producing a thickening of the sebum which becomes a solid plug known as a comedone. When this occurs, hyperkeratinization of the follicular opening is stimulated, thus completely closing the duct. The usual result is a papule, a pustule, or a cyst, often contaminated with bacteria which cause secondary infections. These occurrences characterize the disease state known as acne, and in lesser severity, seborrhea.
Many topical therapeutic agents are employed in the treatment of acne and seborrhea to prevent the blocking of the follicular duct, to reopen the duct once it has become blocked, to act against the infecting bacteria or the thickened sebum, or to provide combinations of each of these actions. The horny outer layer of the skin is formed of dead cells composed largely of a substance known as keratin, and therapeutic agents which act to prevent the blocking of the follicular duct by promoting the removal or sluffing off of excess keratin are known as keratolytic agents. For example, the use of sulfur as a mild cutaneous irritant to remove the horny layer of skin, and with the the debris clogging the follicular openings, is Well known in the art, and other substances such as resorcinol and salicylic acid have also long been used as keratolytic agents in the treatment of acne. It has recently been proposed that benzoyl peroxide, which is a powerful oxidizing agent, be employed as an antibacterial and keratolytic agent in the treatment of acne, and an extensive clinical evaluation of this substance has conclusively demonstrated its eflectiveness for this purpose when employed by itself or, particularly, when employed in conjunction with finely divided sulfur.
ice
Benzoyl peroxide, (C H CO) O is a colorless, odorless, tasteless, crystalline solid that is stable at ordinary room temperatures but which is flammable and is capable of exploding when confined and subjected to grinding heat or flame. It is a powerful oxidizing agent completely non-toxic to man, and because of its lack of local injurious or irritating effects and its lack of penetration into tissue with consequent protein precipitation it has been used topically for its antiseptic and healing properties for many years. More recently, it has been used as a very effective keratolytic and antibacterial agent in the treatment of acne. The material is advantageously incorporated in a cream or ointment base for convenience in applying it to the skin. However, benzoyl peroxide is substantially insoluble in water, and it is ordinarily incorporated in conventional ointments and creams containing water and other common organic and inorganic constituents by first dissolving the peroxide in a volatile organic solvent such as chloroform which is then mixed with the other aqueous and nonaqueous ingredients of the composition. The resulting mixture is then permitted to stand or age for several days in order to allow the organic solvent to evaporate from the composition before it is applied to the skin. However, it has been found that when benzoyl peroxidecontaining compositions prepared in the manner described are kept at a room temperature for a few days, bubbles of gas evolve indicating that some reaction is taking place between the benzoyl peroxide and the base. Experience has shown that most compositions containing benzoyl peroxide, Water and other common organic and mineral components of such preparations display a gradual loss of potency, and that after about four months the level of benzoyl peroxide remaining in the composition is below that necessary to produce the desired therapeutic eiiects. Any attempt to stabilize the composition by adding antioxidants thereto inhibits the acitivity of the benzoyl peroxide and defeats the purpose of the composition. Consequently, it is the usual practice when preparing therapeutic compositions containing benzoyl peroxide to supply the user with separate packages of benzoyl peroxide and a base formulation which are mixed together just prior to using the composition.
SUMMARY OF THE INVENTION We have now discovered that compositions containing water, organic emollients and therapeutically effective benzoyl peroxide can be prepared which are stable over a period of time at least equal to the normal commercial life of ordinary pharmaceutical preparations. Moreover, these new compositions display full stability with respect to the benzoyl peroxide component thereof even when subjected to temperatures higher than those normally expected in the ordinary use of the product. The stability of our new benzoyl peroxide-containing composition is predicated on our discovery that if the base or fluid medium in which the benzoyl peroxide is dispersed contains only water and organic emollients which are substantially inert, non-polar and non-ionic with respect to the other constituents of the composition and which have a boiling point higher than water, the benzoyl peroxide constituent thereof will not be decomposed nor react with the base, and therefore will be able to exert its full therapeutic activity as an oxidizing and kerotolytic agent when applied topically to the skin of a patient. The relative proportions of benzoyl peroxide, water and organic emollients present in the compositions are important only insofar as the composition is therapeutically effective and cosmetically acceptable. Accordingly, the composition of our invention comprises a dispersion of finely divided particles of benzoyl peroxide in a water-containing fluid medium that is substantially free of dissolved benzoyl peroxide, the composition containing from about 1 to 25% by weight of benzoyl peroxide, from about 2 to 25% by weight of at least one organic emollient that is substantially inert, non-polar and non-ionic with respect to the other constituents of the composition and from about 50 to 90% by weight water. The composition also advantageously contains from about 1 to 25 by weight finely divided sulfur, as well as emulsifiers for the aqueous and non-aqueous phases of the fluid medium, antibacterial agents, mold growth inhibitors, and the like. Compositions prepared in accordance with our invention possess a stability which far exceeds the normal requirements for a pharmaceutical product, based upon its normally expected commercial life. For example, when our new compositions are stored at 40 C., 100% of the benzoyl peroxide can be recovered at the end of 12 months. This approximates a normal shelf life of eight years.
DETAILED DESCRIPTION The composition of our invention must contain sufiicient benzoyl peroxide to be therapeutically effective, and should not contain more peroxide than can be uniformly dispersed in the fluid base to form a smoothly spreadable cream or ointment. These considerations dictate that the composition contain at least about 1% and not more than about 25% by weight benzoyl peroxide, and we presently prefer that the composition contain from about 5 to about by weight benzoyl peroxide. The benzoyl peroxide constituent of the composition should be of high purity (that is, in the order of 98:1% (C H CO) O and in the form of relatively finely divided crystalline particles. High purity benzoyl peroxide in the form of dry crystals having a particle size such that at least 99% will pass thru a 60 mesh screen (Tyler Standard) is available commercially, and this form of the peroxide can be blended directly with the other constituents of the composition, without further reduction in the particle size of the peroxide crystals, to form a finished product. However, we presently prefer to employ a somewhat more coarsely crystalline form of benzoyl peroxide that is packaged wet with Water, a fact which greatly increases the safety with which the peroxide can be handled. The wet packed peroxide is dustless, free flowing and disperses readily in the fluid medium comprising the balance of our new composition. The various ingredients of the composition are thoroughly blended together, and the particles of crystalline benzoyl peroxide are simultaneously physically reduced in size, by milling the mixture to obtain a finished composition containing finely divided benzoyl peroxide pursuant to the practice of our invention.
The composition also contains from about 2 to by weight of at least one, and usually several, of certain organic emollients. Specifically, the organic emollient constituents of the composition should be selected from among those which are inert, and which are substantially non-ionic and non-polar, with respect to benzoyl peroxide and the other ingredients of the composition, and further from among those which have a boiling point higher than water. The term inert as employed herein refers to organic emollients which do not react chemically with benzoyl peroxide or with the other constituents of the composition at ambient temperature and pressure. In this connection, we have found that the presence of unsaturated carbon atoms in the emollient has an adverse effect on the stability and shelf life of the composition. Accordingly, the emollients preferably should be saturated organic compounds; that is, organic compounds that have no double or triple carbon to carbon atom bonds in the hydrocarbon chain. The terms non-ionic and non-polar as employed herein refer to emollient organic compounds which are insoluble in water at ordinary temperatures, or if soluble in water do not ionize therein to an appreciable degree. Finally, the requirement that the emollients have a boiling point higher than water is of importance to insure that some of the emollient will remain on the skin of the patient as a vehicle for the benzoyl peroxide after the evaporation of the Water content of the composition therefrom. Emollient compounds meeting these criteria include, but are not limited to, aliphatic alcohols having from 4 to 20 carbon atoms, glycols having 2 to 3 carbon atoms, fatty acids having from 12 to 20 carbon atoms, and the esters of said acids. Specific organic compounds representative of those useful in compositions of our invention include, but are not limited to, butyl alcohol, isobutyl alcohol, amyl alcohol, iso-amyl alcohol, hexyl alcohol, isohexyl alcohol, and the essentially water-insoluble higher aliphatic alcohols which are soluble in or softened by the aforementioned alcohols; ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol and the like; lauric acid, myristic acid, palmitic acid, stearic acid, and the like; and ethyl laurate, isopropyl laurate, ethyl myristate, n-propyl myristate, isopropyl myristate, ethyl palmitate, isopropyl palmitate, methyl palmitate, methyl stearate, ethyl stearate, isopropyl stearate, butyl stearate, isobutyl stearate, amyl stearate, isoamyl stearate, and the like.
In addition, the composition contains from about 50 to by weight water in which benzoyl peroxide is substantially insoluble. Advantageously, it also contains emulsifiers for the aqueous and non-aqueous phases of the composition, for example, polyethylene glycol 1000 monostearate, as well as preservatives such as methyl paraben (the methyl ester of parahydroxybenzoic acid) to prevent mold growth.
The composition also advantageously contains from about 1 to 25% by weight of finely divided sulfur, and preferably from about 2 to 10% by weight of precipitated sulfur, U.S.P. grade. Sulfur is an antimicrobial and keratolytic agent that has long been used in the treatment of acne. Although it is not known precisely how sulfur exerts its keratolytic effect on the skin, it is through that hydrogen sulfide, which is formed when sulfur is in contact with animal tissue, reacts with alkali in tissue fluids to produce active sulfides which, in turn, promote keratolysis. The combination of precipitated sulfur with benzoyl peroxide produces significantly greater keratolysis than either substance will when used alone. The mechanism responsible for this result is not known. However, it may be that the strong oxidizing properties of benzoyl peroxide facilitate the reaction between the active sulfides and keratin, or benzoyl peroxide may have some direct effect or keratin which makes it more susceptible to the action of the sulfide. In any case, the combination of benzoyl peroxide and sulfur in our new composition gives the composition properties which are especially useful in the treatment of acne.
The composition is prepared by carefully and thoroughtly blending the benzoyl peroxide, organic emollient, water and other constituents of the composition. Advantageously, the fluid medium in which the benzoyl peroxide is to be dispersed is first prepared by forming an emulsion of the aqueous and non-aqueous phases of the fluid medium. The benzoyl peroxide and sulfur, if any, constituents of the composition are then added to the emulsion and thoroughly blended therewith to form the therapeutic compostion of our invention. If the benzoyl peroxide constituent is in the form of dry, finely divided crystalline particles no further treatment of the composition is required, However, When the benzoyl peroxide is in the form of relatively coarse crystals packaged wet With water, the mixture of benzoyl peroxide and water is thoroughly mixed with a previously emulsified mixture of the emollient and water constituents of the composition, and the composition is then milled to physically reduce the particle size of the benzoyl peroxide crystals so that substantially all of the particles are smaller than 0.25 mm. in size.
The composition is applied topically to the skin of the patient by rubbing the cream or ointment in well,
once a day, and leaving it on the skin for about two hours after which it is removed by washing with water. If, after two days, treatment remains comfortable, the time of application is increased to four hours daily for four days. Thereafter, nightly applications usually suffice for maintenance as long as no irritation develops. usually at some time within the first four weeks of treatment, a dramatic and suddent generalized peeling or desquamation of the skin occurs in the treated areas. When this occurs, treatment is temporarily discontinued until the reaction subsides, and then application of the composition is resumed at the previous level of treatment.
Almost all persons who use our new composition for the treatment of acne show definite suppression of their eruption within the first few weeks of treatment. The
skin first becomes distinctly less oily, and then begins to desquamate. Individuals with minor to moderate papular and pustular acne show prompt suppression of their eruption and usually are well controlled within three months. Individuals with moderately severe acne show a prompt favorable response but require four to six months to obtain good control. Individuals with severe cystic acne, while slower to respond than those with non-cystic acne, obtain excellent suppression of their eruption within six to nine months in all but a few cases.
The following examples are representative but not limitative of therapeutic compositions prepared in accordance with our invention:
(I) Percent by weight Benzoyl peroxide 5.0 Stearic acid 6.2 Isopropyl palmitate 3.8 Glyceryl monostearate 4.0 Polyethylene glycol 1000 monostearate 5.2 Propylene glycol 2.2 Methyl paraben 0.1 Deionized water 73.5
(II) Percent by weight Benzoyl peroxide 10.0 Palmitic acid 6.2 Isopropyl palmitate 3.8 Glyceryl monostearate 4.0 Polyethylene glycol 1000 monostearate 5.2 Propylene glycol 2.2 Methyl paraben 0.1 Deionized water 68.5
(III) Percent by weight Benzoyl peroxide 5.0 Precipitated sulfur 2.0 Stearic acid 6.2 Ethyl stearate 3.8 Glyceryl monostearate 4.0 Polyethylene glycol 1000 monostearate 5.2 Propylene glycol 2.2 Methyl paraben 0.1 Deionized water 71.5
(IV) Percent by weight Benzoyl peroxide 5.0 Precipitated sulfur 10.0 Stearic acid 6.2 Isopropyl palmitate 3.8 Glyceryl monostearate 4.0 Polyethylene glycol 1000 monostearate 5.2 Ethylene glycol 2.2 Methyl paraben 0.1 Deionized water 63.5
. Percent by weight Benzoyl peroxide 5.0 2.0
Precipitated sulfur Myristic acid 1.6 Amyl stearate 1.0 Glyceryl monostearate 1.0
Polyethylene glycol 1000 monostearate 1.3 Propylene glycol 2.2 Methyl paraben 0.1 Deionized water 85.8
(VI) Percent by weight Benzoyl peroxide 5.0 Precipitated sulfur 10.0 Stearic acid 1.6 Isopropyl palmitate 1.0 Glyceryl laurate 1.0 Polyethylene glycol 1000 monostearate 1.3 Propylene glycol 2.2 Methyl paraben 0.1 Deionized water 77.8
(VII) Percent by weight Benzoyl peroxide 5.0 Stearic acid 1.9 Palmitic acid 1.2 Isopropyl palmitate 1.2 Glyceryl laurate 1.2 Polyethylene glycol 1000 monostearate 2.5 Propylene glycol 2.5 Methyl paraben 0.1 Deionized water 84.4
(VIII) Percent by wt. Benzoyl peroxide 20.0 Laurie acid 1.4 Isoamyl stearate 1.9 Glyceryl monostearate 1.9 Polyethylene glycol 1000 monostearate 1.2 Propylene glycol 2.0 Methyl paraben 0.1 Deionized water 71.5
(IX) Percent by wt. Benzoyl peroxide 10.0 Precipitated sulfur 10.0 Stearic acid 0.7 Isopropyl palmitate 0.45 Glyceryl monostearate 0.45 Polyethylene glycol 1000 monostearate 0.6 Diethylene glycol 1.0 Methyl paraben 0.1 Deionized water 76.7
(X) Percent by wt. Benzoyl peroxide 20.0 Precipitated sulfur 25.0 Lauryl alcohol 0.4 Isopropyl palmitate 0.3 Glyceryl monostearate 0.3 Polyethylene glycol 1000 monostearate 0.4 Propylene glycol 0.6 Methyl paraben 0.1 Deionized water 52.9
The most widely used composition of our invention contains 5% benzoyl peroxide and 2% sulfur. However, compositions containing 20% benzoyl peroxide and up to 25% sulfur have been used by individuals with dark, very oily skin and by those who have developed resistance to compositions of lesser strength, and compositions containing only 1.25% benzoyl peroxide and 0.5% sulfur have been used by individuals with fair and delicate skin. In all cases the compositions prepared in accordance with our invention are stable and retain full potency of the benzoyl peroxide constituent thereof for a period of time, i.e., for about eight years or more, which far exceeds the normal requirements for a pharmaceutical product.
From the foregoing description of our new composition for the treatment of acne it will be seen that we have made an important contribution to the art to which our invention relates.
We claim:
1. A therapeutic composition for the treatment of acne that is stable in storage Without the addition of a stabilizer thereto which consists of a uniform dispersion of finely divided particles of crystalline benzoyl peroxide in a fluid medium consisting essentially of water and an organic emollient selected from the group consisting of saturated aliphatic alcohols having from 4 to 20 carbon atoms, glycols having 2 to 3 carbon atoms, saturated fatty acids having from 12 to 20 carbon atoms, lower alkyl and glyceryl esters of said fatty acids having from 12 to 20 carbon atoms, and mixtures thereof, said organic emollient being inert, non-polar and non-ionic with respect to the other constituents of the composition and that have a boiling point higher than water, said composition containing from about 1 to 25% by weight benzoyl peroxide, from about 2 to 25% by weight of said organic emollient and from about 50 to 90% by weight water.
2. The therapeutic composition according to claim 1 in which the composition contains from about 5 to 10% by weight benzoyl peroxide.
3. The therapeutic composition according to claim 1 in which the composition contains from about 1 to 25% by weight finely divided sulfur.
4. The therapeutic composition according to claim 1 in which the composition contains from about 5 to 10% by weight benzoyl peroxide and from about 2 to 10% by weight finely divided sulfur.
References Cited UNITED STATES PATENTS 735,930 8/1962 Klaron.
FOREIGN PATENTS 793,471 11/ 1935 France.
821,726 10/1959 Great Britain.
OTHER REFERENCES ALBERT T. MEYERS, Primary Examiner D. R. ORE, Assistant Examiner US. Cl. X.R. 424-338
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71186168A | 1968-03-11 | 1968-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3535422A true US3535422A (en) | 1970-10-20 |
Family
ID=24859841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US711861A Expired - Lifetime US3535422A (en) | 1968-03-11 | 1968-03-11 | Stable benzoyl peroxide composition |
Country Status (1)
Country | Link |
---|---|
US (1) | US3535422A (en) |
Cited By (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2418386A1 (en) * | 1973-04-16 | 1974-10-31 | Stiefel Laboratories | PRODUCTS FOR TREATMENT OF ACNE |
US4075353A (en) * | 1976-06-09 | 1978-02-21 | Dermatologics For Veterinary Medicine, Inc. | Process for the treatment of acarid skin infections in animals |
US4129647A (en) * | 1977-10-17 | 1978-12-12 | Edmund Klein | Treatment of acne |
US4163800A (en) * | 1977-08-17 | 1979-08-07 | The Procter & Gamble Company | Topical composition and treatment of skin lesions therewith |
US4189501A (en) * | 1977-10-07 | 1980-02-19 | A. H. C. Pharmacal, Inc. | Composition and method for the treatment of acne |
EP0013459A2 (en) * | 1979-01-08 | 1980-07-23 | THE PROCTER & GAMBLE COMPANY | Topical anti-acne compositions |
US4228163A (en) * | 1979-03-30 | 1980-10-14 | Dermik Laboratories | Method for treating pseudofolliculitis barbae |
US4297348A (en) * | 1980-04-11 | 1981-10-27 | Rush-Hampton Industries, Inc. | Composition and method for the treatment of acne |
US4318907A (en) * | 1978-04-04 | 1982-03-09 | Westwood Pharmaceuticals, Inc. | Method for treating acne vulgaris and compositions useful for that purpose |
US4335115A (en) * | 1976-11-01 | 1982-06-15 | The Procter & Gamble Company | Anti-acne composition |
US4350681A (en) * | 1977-10-07 | 1982-09-21 | A.H.C. Pharmacal, Inc. | Stabilized benzoyl peroxide compositions |
US4355028A (en) * | 1978-04-04 | 1982-10-19 | Westwood Pharmaceuticals, Inc. | Composition for treating acne vulgaris |
US4361584A (en) * | 1977-10-07 | 1982-11-30 | A.H.C. Pharmacal, Inc. | Composition and method for the treatment of acne |
US4364940A (en) * | 1981-02-23 | 1982-12-21 | Usv Pharmaceutical Corporation | Compositions for treating acne |
FR2517203A1 (en) * | 1981-12-01 | 1983-06-03 | Wolff Chem Pharm Gmbh | COMPOSITION FOR THE TREATMENT OF ACNE |
US4387107A (en) * | 1979-07-25 | 1983-06-07 | Dermik Laboratories, Inc. | Stable benzoyl peroxide composition |
US4401835A (en) * | 1981-09-17 | 1983-08-30 | Warner-Lambert Company | Method for preparing small sized benzoyl peroxide crystals |
EP0129283A2 (en) * | 1983-06-21 | 1984-12-27 | The Procter & Gamble Company | Improved penetrating topical pharmaceutical compositions containing corticosteroids |
EP0129284A2 (en) | 1983-06-21 | 1984-12-27 | THE PROCTER & GAMBLE COMPANY | Improved penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4514384A (en) * | 1983-03-14 | 1985-04-30 | Gallina Damian J | Hemorrhoid treatment method |
US4518583A (en) * | 1983-02-22 | 1985-05-21 | Gallina Damian J | Hemorrhoid and anorectal disease treatment method |
US4537776A (en) * | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
US4540567A (en) * | 1976-10-15 | 1985-09-10 | Lever Brothers Company | Cosmetic composition |
US4545990A (en) * | 1982-11-22 | 1985-10-08 | L'oreal | Anti-acne composition |
EP0164716A2 (en) * | 1984-06-11 | 1985-12-18 | Richardson-Vicks, Inc. | Stabilized clear benzoyl peroxide compositions |
FR2604435A1 (en) * | 1986-09-30 | 1988-04-01 | Oreal | UNSATURATED AROMATIC PEROXIDES AND THEIR USE IN THERAPEUTICS AND COSMETICS |
US4900721A (en) * | 1986-06-09 | 1990-02-13 | Henkel Kommanditgesellschaft Auf Aktien | Disinfectants and their use for disinfecting the skin and mucous membrane |
EP0331489A3 (en) * | 1988-03-03 | 1990-03-28 | Parke Davis Pty. Ltd. | Acne treatment |
US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
US5041439A (en) * | 1986-06-13 | 1991-08-20 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
US5057501A (en) * | 1990-03-13 | 1991-10-15 | Dermatologic Research Corporation | Methods for treatment of papulosquamous and eczematous diseases |
US5057479A (en) * | 1990-05-09 | 1991-10-15 | Witco Corporation | Aqueous dispersions of aromatic diacyl peroxides |
US5057500A (en) * | 1990-02-12 | 1991-10-15 | Dermatologic Research Corporation | Treatment of pruritis with esters and amides |
US5162280A (en) * | 1988-01-27 | 1992-11-10 | Witco Corporation | Aqueous dispersions of aromatic diacyl peroxides |
US5204093A (en) * | 1989-04-06 | 1993-04-20 | Victor Steven A | Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same |
US5231087A (en) * | 1988-03-16 | 1993-07-27 | Cellegy Pharmaceuticals, Inc. | Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids |
US5260390A (en) * | 1980-01-16 | 1993-11-09 | Akzo N.V. | Peroxide emulsions containing an antifreezing compound |
US5300600A (en) * | 1989-10-12 | 1994-04-05 | Witco Corporation | Aqueous dispersions of peroxides |
US5470884A (en) * | 1994-05-19 | 1995-11-28 | Procter & Gamble | Anti-acne compositions |
US5733886A (en) * | 1992-02-18 | 1998-03-31 | Lloyd J. Baroody | Compositions of clindamycin and benzoyl peroxide for acne treatment |
US5767098A (en) * | 1985-12-12 | 1998-06-16 | Dermik Laboratories, Inc. | Anti-acne method and composition |
US6013637A (en) * | 1998-06-12 | 2000-01-11 | Dermik Laboratories Inc. | Anti-acne method and composition |
US6433024B1 (en) | 2000-05-08 | 2002-08-13 | Karl F. Popp | Topical anti-acne composition |
US6462025B2 (en) | 2000-12-12 | 2002-10-08 | Imaginative Research Associates, Inc. | Antibiotic/benzoyl peroxide dispenser |
US20040132938A1 (en) * | 2001-03-23 | 2004-07-08 | O Boen Ho | Storage stable aqueous organic peroxide emulsions |
US6774100B2 (en) | 2000-12-06 | 2004-08-10 | Imaginative Research Associates, Inc. | Anhydrous creams, lotions and gels |
US20040157766A1 (en) * | 2003-01-23 | 2004-08-12 | Edko Trading And Representation Co. Ltd. | Topical pharmaceutical and/or cosmetic dispense systems |
US20050100585A1 (en) * | 2003-07-03 | 2005-05-12 | Patel Bhiku G. | Delivery system for topical medications |
US20060019935A1 (en) * | 2004-07-20 | 2006-01-26 | Watson Dana M | Composition and method for treating acne including anti-inflammatory Hepes Oleate |
US7060732B2 (en) | 2000-12-12 | 2006-06-13 | Imaginative Research Associates, Inc. | Antibiotic/benzoyl peroxide dispenser |
US20060189552A1 (en) * | 2000-12-12 | 2006-08-24 | Mohan Vishnupad | Dispenser for dispensing three or more actives |
US20080033031A1 (en) * | 2004-11-19 | 2008-02-07 | Aventis Pharmaceuticals Inc. | Antibiotic compounds, compositions and methods of treatment |
FR2910321A1 (en) * | 2006-12-21 | 2008-06-27 | Galderma Res & Dev S N C Snc | Composition comprising a retinoid and benzoyl peroxide, e.g. for treating acne, is in the form of a gel cream |
FR2910320A1 (en) * | 2006-12-21 | 2008-06-27 | Galderma Res & Dev S N C Snc | Stable dermatological or cosmetic composition, useful e.g. for combating acne vulgaris or skin aging, comprises emulsion containing retinoid and benzoyl peroxide in dispersed form |
US20080176954A1 (en) * | 2001-12-21 | 2008-07-24 | Galderma Research & Development, S.N.C. | Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide |
US20090234027A1 (en) * | 2008-03-14 | 2009-09-17 | Nathan Strick | Topical gel cosmetic formulation of cellacefate for the control of acne and rosacea |
US20100099733A1 (en) * | 2008-10-20 | 2010-04-22 | Gordon Jay Dow | Method for obtaining a stable dispersion of benzoyl peroxide |
US20100143285A1 (en) * | 2006-11-28 | 2010-06-10 | Galderma Research & Development, Biot, France. | Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer |
US20110092562A1 (en) * | 2009-10-21 | 2011-04-21 | Gordon Jay Dow | Method for wetting a powder containing benzoyl peroxide |
WO2014076136A1 (en) * | 2012-11-13 | 2014-05-22 | Galderma S.A. | Bpo wash emulsion composition |
WO2016077818A1 (en) | 2014-11-14 | 2016-05-19 | Melinta Therapeutics, Inc. | Method for treating, preventing, or reducing the risk of skin infection |
WO2017200979A1 (en) | 2016-05-17 | 2017-11-23 | Melinta Therapeutics, Inc. | Topical formulations of biaryl heterocyclic compounds and methods of use thereof |
US10610594B2 (en) | 2012-11-13 | 2020-04-07 | Galderma S.A. | BPO wash gel composition |
US10688117B2 (en) | 2011-05-27 | 2020-06-23 | Galderma S.A. | Topical wash composition for use in acne patients |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US735930A (en) * | 1902-09-18 | 1903-08-11 | Chicago Motor Vehicle Company | Engine-governor. |
FR793471A (en) * | 1934-08-01 | 1936-01-25 | Autoxygen | Improvement in the manufacturing process of a cosmetic composition |
GB821726A (en) * | 1956-03-06 | 1959-10-14 | Pierre Francoise Isidore Josep | Cosmetic product for skin treatment |
-
1968
- 1968-03-11 US US711861A patent/US3535422A/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US735930A (en) * | 1902-09-18 | 1903-08-11 | Chicago Motor Vehicle Company | Engine-governor. |
FR793471A (en) * | 1934-08-01 | 1936-01-25 | Autoxygen | Improvement in the manufacturing process of a cosmetic composition |
GB821726A (en) * | 1956-03-06 | 1959-10-14 | Pierre Francoise Isidore Josep | Cosmetic product for skin treatment |
Cited By (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4056611A (en) * | 1973-04-16 | 1977-11-01 | Stiefel Laboratories, Inc. | Therapeutic composition |
DE2418386A1 (en) * | 1973-04-16 | 1974-10-31 | Stiefel Laboratories | PRODUCTS FOR TREATMENT OF ACNE |
US4075353A (en) * | 1976-06-09 | 1978-02-21 | Dermatologics For Veterinary Medicine, Inc. | Process for the treatment of acarid skin infections in animals |
US4540567A (en) * | 1976-10-15 | 1985-09-10 | Lever Brothers Company | Cosmetic composition |
US4335115A (en) * | 1976-11-01 | 1982-06-15 | The Procter & Gamble Company | Anti-acne composition |
US4163800A (en) * | 1977-08-17 | 1979-08-07 | The Procter & Gamble Company | Topical composition and treatment of skin lesions therewith |
US4350681A (en) * | 1977-10-07 | 1982-09-21 | A.H.C. Pharmacal, Inc. | Stabilized benzoyl peroxide compositions |
US4189501A (en) * | 1977-10-07 | 1980-02-19 | A. H. C. Pharmacal, Inc. | Composition and method for the treatment of acne |
US4361584A (en) * | 1977-10-07 | 1982-11-30 | A.H.C. Pharmacal, Inc. | Composition and method for the treatment of acne |
US4129647A (en) * | 1977-10-17 | 1978-12-12 | Edmund Klein | Treatment of acne |
US4355028A (en) * | 1978-04-04 | 1982-10-19 | Westwood Pharmaceuticals, Inc. | Composition for treating acne vulgaris |
US4318907A (en) * | 1978-04-04 | 1982-03-09 | Westwood Pharmaceuticals, Inc. | Method for treating acne vulgaris and compositions useful for that purpose |
EP0013459A2 (en) * | 1979-01-08 | 1980-07-23 | THE PROCTER & GAMBLE COMPANY | Topical anti-acne compositions |
US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
EP0013459A3 (en) * | 1979-01-08 | 1981-05-13 | THE PROCTER & GAMBLE COMPANY | Topical anti-acne compositions |
US4228163A (en) * | 1979-03-30 | 1980-10-14 | Dermik Laboratories | Method for treating pseudofolliculitis barbae |
US4387107A (en) * | 1979-07-25 | 1983-06-07 | Dermik Laboratories, Inc. | Stable benzoyl peroxide composition |
US5369197A (en) * | 1980-01-16 | 1994-11-29 | Akzo N.V. | Peroxide emulsions containing an antifreezing compound |
US5260390A (en) * | 1980-01-16 | 1993-11-09 | Akzo N.V. | Peroxide emulsions containing an antifreezing compound |
US4297348A (en) * | 1980-04-11 | 1981-10-27 | Rush-Hampton Industries, Inc. | Composition and method for the treatment of acne |
US4364940A (en) * | 1981-02-23 | 1982-12-21 | Usv Pharmaceutical Corporation | Compositions for treating acne |
US4401835A (en) * | 1981-09-17 | 1983-08-30 | Warner-Lambert Company | Method for preparing small sized benzoyl peroxide crystals |
FR2517203A1 (en) * | 1981-12-01 | 1983-06-03 | Wolff Chem Pharm Gmbh | COMPOSITION FOR THE TREATMENT OF ACNE |
US4545990A (en) * | 1982-11-22 | 1985-10-08 | L'oreal | Anti-acne composition |
US4518583A (en) * | 1983-02-22 | 1985-05-21 | Gallina Damian J | Hemorrhoid and anorectal disease treatment method |
US4514384A (en) * | 1983-03-14 | 1985-04-30 | Gallina Damian J | Hemorrhoid treatment method |
US4552872A (en) * | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
EP0129283A2 (en) * | 1983-06-21 | 1984-12-27 | The Procter & Gamble Company | Improved penetrating topical pharmaceutical compositions containing corticosteroids |
EP0129284A2 (en) | 1983-06-21 | 1984-12-27 | THE PROCTER & GAMBLE COMPANY | Improved penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4557934A (en) * | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4537776A (en) * | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
EP0129283A3 (en) * | 1983-06-21 | 1987-11-11 | The Procter & Gamble Company | Improved penetrating topical pharmaceutical compositions containing corticosteroids |
US4609674A (en) * | 1984-06-11 | 1986-09-02 | Richardson-Vicks Inc. | Stabilized clear benzoyl peroxide compositions |
EP0164716A3 (en) * | 1984-06-11 | 1986-08-20 | Richardson-Vicks, Inc. | Stabilized clear benzoyl peroxide compositions |
EP0164716A2 (en) * | 1984-06-11 | 1985-12-18 | Richardson-Vicks, Inc. | Stabilized clear benzoyl peroxide compositions |
US5767098A (en) * | 1985-12-12 | 1998-06-16 | Dermik Laboratories, Inc. | Anti-acne method and composition |
US4900721A (en) * | 1986-06-09 | 1990-02-13 | Henkel Kommanditgesellschaft Auf Aktien | Disinfectants and their use for disinfecting the skin and mucous membrane |
US5041439A (en) * | 1986-06-13 | 1991-08-20 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
FR2604435A1 (en) * | 1986-09-30 | 1988-04-01 | Oreal | UNSATURATED AROMATIC PEROXIDES AND THEIR USE IN THERAPEUTICS AND COSMETICS |
US4803228A (en) * | 1986-09-30 | 1989-02-07 | L'oreal | Unsaturated aromatic peroxides and their use in pharmaceutical and cosmetic compositions |
BE1004154A4 (en) * | 1986-09-30 | 1992-10-06 | Oreal | Aromatic unsaturated peroxides and therapeutic use and cosmetics. |
US5162280A (en) * | 1988-01-27 | 1992-11-10 | Witco Corporation | Aqueous dispersions of aromatic diacyl peroxides |
EP0331489A3 (en) * | 1988-03-03 | 1990-03-28 | Parke Davis Pty. Ltd. | Acne treatment |
AU619256B2 (en) * | 1988-03-03 | 1992-01-23 | Connetics Australia Pty Ltd | Acne treatment |
US5231087A (en) * | 1988-03-16 | 1993-07-27 | Cellegy Pharmaceuticals, Inc. | Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids |
US5204093A (en) * | 1989-04-06 | 1993-04-20 | Victor Steven A | Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same |
US5300600A (en) * | 1989-10-12 | 1994-04-05 | Witco Corporation | Aqueous dispersions of peroxides |
US5057500A (en) * | 1990-02-12 | 1991-10-15 | Dermatologic Research Corporation | Treatment of pruritis with esters and amides |
US5057501A (en) * | 1990-03-13 | 1991-10-15 | Dermatologic Research Corporation | Methods for treatment of papulosquamous and eczematous diseases |
US5057479A (en) * | 1990-05-09 | 1991-10-15 | Witco Corporation | Aqueous dispersions of aromatic diacyl peroxides |
US5733886A (en) * | 1992-02-18 | 1998-03-31 | Lloyd J. Baroody | Compositions of clindamycin and benzoyl peroxide for acne treatment |
US5470884A (en) * | 1994-05-19 | 1995-11-28 | Procter & Gamble | Anti-acne compositions |
US6013637A (en) * | 1998-06-12 | 2000-01-11 | Dermik Laboratories Inc. | Anti-acne method and composition |
US6433024B1 (en) | 2000-05-08 | 2002-08-13 | Karl F. Popp | Topical anti-acne composition |
US6774100B2 (en) | 2000-12-06 | 2004-08-10 | Imaginative Research Associates, Inc. | Anhydrous creams, lotions and gels |
US20060173076A1 (en) * | 2000-12-12 | 2006-08-03 | Mohan Vishnupad | Antibiotic/benzoyl peroxide dispenser |
US6462025B2 (en) | 2000-12-12 | 2002-10-08 | Imaginative Research Associates, Inc. | Antibiotic/benzoyl peroxide dispenser |
US20060189552A1 (en) * | 2000-12-12 | 2006-08-24 | Mohan Vishnupad | Dispenser for dispensing three or more actives |
US7060732B2 (en) | 2000-12-12 | 2006-06-13 | Imaginative Research Associates, Inc. | Antibiotic/benzoyl peroxide dispenser |
US20060172955A1 (en) * | 2000-12-12 | 2006-08-03 | Mohan Vishnupad | Antibiotic/benzoyl peroxide dispenser |
US20040132938A1 (en) * | 2001-03-23 | 2004-07-08 | O Boen Ho | Storage stable aqueous organic peroxide emulsions |
US7214329B2 (en) * | 2001-03-23 | 2007-05-08 | Akzo Nobel N.V. | Storage stable aqueous organic peroxide emulsions |
US8936800B2 (en) | 2001-12-21 | 2015-01-20 | Galderma Research & Development | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
US9814690B2 (en) | 2001-12-21 | 2017-11-14 | Galderma Research & Development | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
US20110070274A1 (en) * | 2001-12-21 | 2011-03-24 | Galderma Research & Development | Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide |
US20080176954A1 (en) * | 2001-12-21 | 2008-07-24 | Galderma Research & Development, S.N.C. | Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide |
US8241649B2 (en) | 2001-12-21 | 2012-08-14 | Galderma Research & Development | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide |
US8105618B2 (en) | 2001-12-21 | 2012-01-31 | Galderma Research & Development | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide |
US20040157766A1 (en) * | 2003-01-23 | 2004-08-12 | Edko Trading And Representation Co. Ltd. | Topical pharmaceutical and/or cosmetic dispense systems |
US20110313051A1 (en) * | 2003-07-03 | 2011-12-22 | Patel Bhiku G | Delivery system for topical medications |
US20050100585A1 (en) * | 2003-07-03 | 2005-05-12 | Patel Bhiku G. | Delivery system for topical medications |
US20070110794A1 (en) * | 2003-07-03 | 2007-05-17 | Patel Bhiku G | Delivery system for topical medications |
US20060019935A1 (en) * | 2004-07-20 | 2006-01-26 | Watson Dana M | Composition and method for treating acne including anti-inflammatory Hepes Oleate |
US20080033031A1 (en) * | 2004-11-19 | 2008-02-07 | Aventis Pharmaceuticals Inc. | Antibiotic compounds, compositions and methods of treatment |
US8568704B2 (en) * | 2006-11-28 | 2013-10-29 | Galderma Research & Development | Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer |
US20100143285A1 (en) * | 2006-11-28 | 2010-06-10 | Galderma Research & Development, Biot, France. | Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer |
CN101631594A (en) * | 2006-12-21 | 2010-01-20 | 盖尔德马研究及发展公司 | Emulsion comprising at least one retinoid and benzoyl peroxide |
FR2910320A1 (en) * | 2006-12-21 | 2008-06-27 | Galderma Res & Dev S N C Snc | Stable dermatological or cosmetic composition, useful e.g. for combating acne vulgaris or skin aging, comprises emulsion containing retinoid and benzoyl peroxide in dispersed form |
US20090318550A1 (en) * | 2006-12-21 | 2009-12-24 | Galderma Research & Development | Emulsions comprising at least one retinoid and benzoyl peroxide |
US20100166852A1 (en) * | 2006-12-21 | 2010-07-01 | Galderma Research & Development | Cream gels comprising at least one retinoid and benzoyl peroxide |
US10925814B2 (en) | 2006-12-21 | 2021-02-23 | Galderma Research & Development | Cream gels comprising at least one retinoid and benzoyl peroxide |
US10702466B2 (en) | 2006-12-21 | 2020-07-07 | Galderma Research & Development | Emulsions comprising at least one retinoid and benzoyl peroxide |
WO2008087354A3 (en) * | 2006-12-21 | 2008-11-13 | Galderma Res & Dev | Cream-gel comprising at least one retinoid and benzoyl peroxide |
WO2008087348A3 (en) * | 2006-12-21 | 2008-11-06 | Galderma Res & Dev | Emulsion comprising at least one retinoid and benzoyl peroxide |
EP2460561A1 (en) * | 2006-12-21 | 2012-06-06 | Galderma Research & Development | Emulsion comprising at least one retinoid and benzoyl peroxide |
EP2460562A1 (en) * | 2006-12-21 | 2012-06-06 | Galderma Research & Development | Cream-gel comprising at least one retinoid and benzoyl peroxide |
WO2008087354A2 (en) * | 2006-12-21 | 2008-07-24 | Galderma Research & Development | Cream-gel comprising at least one retinoid and benzoyl peroxide |
WO2008087348A2 (en) * | 2006-12-21 | 2008-07-24 | Galderma Research & Development | Emulsion comprising at least one retinoid and benzoyl peroxide |
US9999577B2 (en) * | 2006-12-21 | 2018-06-19 | Galderma Research & Development | Cream gels comprising at least one retinoid and benzoyl peroxide |
FR2910321A1 (en) * | 2006-12-21 | 2008-06-27 | Galderma Res & Dev S N C Snc | Composition comprising a retinoid and benzoyl peroxide, e.g. for treating acne, is in the form of a gel cream |
US8957112B2 (en) | 2006-12-21 | 2015-02-17 | Galderma Research & Development | Cream gels comprising at least one retinoid and benzoyl peroxide |
US20150098918A1 (en) * | 2006-12-21 | 2015-04-09 | Galderma Research & Development | Cream gels comprising at least one retinoid and benzoyl peroxide |
EP3025763A1 (en) * | 2006-12-21 | 2016-06-01 | Galderma Research & Development | Cream gel comprising at least one retinoid and benzoyl peroxide |
US20090234027A1 (en) * | 2008-03-14 | 2009-09-17 | Nathan Strick | Topical gel cosmetic formulation of cellacefate for the control of acne and rosacea |
US20100099733A1 (en) * | 2008-10-20 | 2010-04-22 | Gordon Jay Dow | Method for obtaining a stable dispersion of benzoyl peroxide |
US9744150B2 (en) * | 2009-10-21 | 2017-08-29 | Dow Pharmaceutical Sciences Inc. | Suspension containing micronized benzoyl peroxide |
US20110092562A1 (en) * | 2009-10-21 | 2011-04-21 | Gordon Jay Dow | Method for wetting a powder containing benzoyl peroxide |
US10688117B2 (en) | 2011-05-27 | 2020-06-23 | Galderma S.A. | Topical wash composition for use in acne patients |
WO2014076136A1 (en) * | 2012-11-13 | 2014-05-22 | Galderma S.A. | Bpo wash emulsion composition |
US10610594B2 (en) | 2012-11-13 | 2020-04-07 | Galderma S.A. | BPO wash gel composition |
US11446272B2 (en) | 2012-11-13 | 2022-09-20 | Galderma Holding SA | BPO wash emulsion composition |
WO2016077818A1 (en) | 2014-11-14 | 2016-05-19 | Melinta Therapeutics, Inc. | Method for treating, preventing, or reducing the risk of skin infection |
US10471046B2 (en) | 2014-11-14 | 2019-11-12 | Melinta Subsidary Corp. | Method for treating, preventing, or reducing the risk of skin infection |
WO2017200979A1 (en) | 2016-05-17 | 2017-11-23 | Melinta Therapeutics, Inc. | Topical formulations of biaryl heterocyclic compounds and methods of use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3535422A (en) | Stable benzoyl peroxide composition | |
US4056611A (en) | Therapeutic composition | |
US4387107A (en) | Stable benzoyl peroxide composition | |
US4545990A (en) | Anti-acne composition | |
US3906108A (en) | Stabilized tretinoin cream emulsion | |
US4923900A (en) | Therapeutic compositions containing benzoyl peroxide | |
US5397497A (en) | Bath additive composition containing polyglycerol fatty acid ester mixture | |
US6433024B1 (en) | Topical anti-acne composition | |
US5503825A (en) | Lip balm composition | |
US5086075A (en) | Therapeutic compositions containing benzoyl peroxide | |
US4178373A (en) | Coal tar gel composition | |
US4593046A (en) | Method of reducing skin irritation from benzoyl peroxide | |
JPS60142920A (en) | Anti-acne agent | |
PT94485A (en) | METHOD FOR PREPARING A STABLE, COSMETICALLY ACCEPTABLE TOPIC GEL FORMULA, CONTAINING A TETRACYCLINE, USEFUL IN ACNE TREATMENT | |
EP0831768A1 (en) | Topical vehicles containing solubilized and stabilized azelaic acid | |
JPH0215022A (en) | Anti-imflammatory skin wetting composition and preparation thereof | |
HUT53518A (en) | Process for producing skin moistening pharmaceutical composition comprising vitamins a as active ingredient | |
US6210693B1 (en) | Oil-in-water type emulsified composition | |
JPS5883648A (en) | Lanolin acid copper and local composition | |
CA1156558A (en) | Stable benzoyl peroxide composition | |
US4062937A (en) | Insect bite relief preparation | |
EP0304802A2 (en) | Pharmaceutical composition and the use thereof | |
US5728690A (en) | Clear non-alcoholic hydrocortisone solutions | |
CA1099636A (en) | Dithranol composition for the treatment of psoriasis | |
US20100010091A1 (en) | Anhydrous, Dermatological or Cosmetic Preparation Containing Urea |